The Gamaleya Institute is ready to file papers to Russian Health Ministry to obtain permission for research of new platforms for COVID vaccines, Institute Director Alexander Gintsburg told TASS.
Earlier, Institute Deputy Director Denis Logunov said that the researchers were looking into development of a polyvalent vaccine against the coronavirus infection, based on several viral strains at the same time, for example, delta and omicron strains.